BioNReg CMC Consulting — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

BioNReg CMC Consulting is a specialized regulatory affairs CMC consultancy founded in 2019 and formally launched in 2023 by Dr. Jean-Marc Wilkin, a senior regulatory professional with over 23 years of industry experience, primarily at GSK Vaccines. The firm offers tailored services including regulatory strategy, Module 3 authoring, interim management, and issue resolution for complex biologics such as vaccines, antibodies, and advanced therapies. It targets small to mid-sized biotech and pharma companies facing CMC challenges, positioning itself as a flexible, expert resource in a niche but critical segment of drug development.

Regulatory AffairsCMC Consulting

Technology Platform

The company does not own a technology platform; it is a consultancy leveraging deep regulatory CMC expertise in biologics (vaccines, antibodies, gene therapy, etc.) and a project-oriented service model.

Opportunities

Growing demand from small/virtual biotech companies lacking in-house CMC expertise, especially for complex biologics and advanced therapies.

The trend towards outsourcing and the constant need for post-approval lifecycle management provide a steady stream of potential projects.

Risk Factors

High dependency on the founder as a single point of failure.

Revenue is project-based and vulnerable to cyclical funding in the biotech sector.

Faces competition from large CROs and other niche consultants.

Competitive Landscape

Competes with large global Contract Research Organizations (CROs) offering full-service regulatory affairs and numerous independent freelance consultants. Differentiation is based on deep, hands-on expertise in CMC for a wide range of biologics and a flexible, personalized service model.

More companies in Digital Health & Biotech SaaS →More companies in Belgium →